Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
RemeGen Co. Ltd. Class H ( (HK:9995) ) has issued an announcement.
RemeGen Co., Ltd. has scheduled a board meeting for April 28, 2026, to review and approve the unaudited first-quarter results for the three months ended March 31, 2026. The company also plans to publish these results after board approval, signaling upcoming disclosure of its early 2026 financial performance to the market.
The announcement confirms the current composition of RemeGen’s board, listing its executive, non-executive, and independent non-executive directors. This disclosure underscores the company’s adherence to corporate governance and transparency requirements expected of issuers on the Hong Kong Stock Exchange.
The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company incorporated in the People’s Republic of China and listed in Hong Kong under stock code 9995. The company operates through a board structure that includes executive, non-executive, and independent non-executive directors overseeing its activities and financial reporting for shareholders and other stakeholders.
Average Trading Volume: 4,122,979
Technical Sentiment Signal: Buy
Current Market Cap: HK$85.01B
Learn more about 9995 stock on TipRanks’ Stock Analysis page.